Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT00095901Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2004
- Primary completion
- May 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Rate of Response at 4 weeks. Started Jun 2004; status: completed.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00095901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095901.